Teyi Pharmaceutical announced that the company's drug compound sulfamethoxazole tablets passed the consistency evaluation.
According to the 2021 third quarter report of Teyi Pharmaceutical, the company's main revenue was 525 million yuan, up 21.33% year-on-year; the net profit attributable to the mother was 103 million yuan, up 257.54% year-on-year; the deduction of non-net profit was 89.4285 million yuan, up 255.09% year-on-year; among them, in the third quarter of 2021, the company's single-quarter main revenue was 167 million yuan, up 25.76% year-on-year; the single-quarter net profit attributable to the mother was 27.5536 million yuan, up 1895.21% year-on-year. In the single quarter, the non-net profit was 26.8111 million yuan, up 352.95% year-on-year; the debt ratio was 45.29%, the investment income was 6.3073 million yuan, the financial expenses were 21.625 million yuan, and the gross profit margin was 52.85%.
The unit has not had an institutional rating in the last 90 days. The Securities Star Valuation Analysis Tool shows that the 002728) good company rating is 2.5 stars, good price rating is 2.5 stars, and valuation comprehensive rating is 2.5 stars.
The chairman of the company is Xu Danqing. Mr. Xu Danqing: Born in November 1969, Chinese nationality, master's degree, long-term engaged in medicinal materials trading and other business, once served as the chairman and general manager of Zhengtian Pharmaceutical, the director and general manager of Taicheng Pharmaceutical Co., Ltd. He is currently the chairman and general manager of Teyi Pharmaceutical Group Co., Ltd., a director of the Guangdong Pharmaceutical Industry Association, an executive vice president of the Jiangmen Enterprise Confederation and a standing committee member of the 15th People's Congress of Taishan City, and was rated as "Guangdong Famous Entrepreneur in the Pharmaceutical Industry" by the Guangdong Pharmaceutical Industry Association in December 2011.
This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if there are any problems in the text, please contact us.